¡Ya estamos en ! Descubre más
icono de IMGN

Immunogen Inc
IMGN

Excluida de cotización

IMGN dejó de cotizar en bolsa el 9 de febrero de 2024.

Volver al ranking
 

Acerca de: Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Empleados: 277

Atención médica Fabricantes de medicamentos - General

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%
Positivo
Zacks Investment Research
hace 2 años
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Positivo
Zacks Investment Research
hace 2 años
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Positivo
InvestorPlace
hace 2 años
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.
Neutral
Business Wire
hace 2 años
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positivo
Zacks Investment Research
hace 2 años
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
Positivo
CNBC
hace 2 años
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Positivo
Zacks Investment Research
hace 2 años
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positivo
Zacks Investment Research
hace 2 años
Best Momentum Stocks to Buy for January 4th
IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.
Positivo
Zacks Investment Research
hace 2 años
New Strong Buy Stocks for January 4th
IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.
Neutral
Business Wire
hace 2 años
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ver rankings de noticias
Gráficos de precios implementados con Lightweight Charts™